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Aspirin but not ibuprofen use is associated with reduced risk
of prostate cancer: a PLCO Study
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BACKGROUND:

Although most epidemiological studies suggest that non-steroidal anti-inflammatory drug use is inversely associated
with prostate cancer risk, the magnitude and specificity of this association remain unclear.
METHODS: We examined self-reported aspirin and ibuprofen use in relation to prostate cancer risk among 29 450 men ages 55–74
who were initially screened for prostate cancer from 1993 to 2001 in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening
Trial. Men were followed from their first screening exam until 31 December 2009, during which 3575 cases of prostate cancer
were identified.
RESULTS: After adjusting for potential confounders, the hazard ratios (HRs) of prostate cancer associated with o1 and X1 pill of
aspirin daily were 0.98 (95% confidence interval (CI), 0.90–1.07) and 0.92 (95% CI: 0.85–0.99), respectively, compared with never use
(P for trend 0.04). The effect of taking at least one aspirin daily was more pronounced when restricting the analyses to men older than
age 65 or men who had a history of cardiovascular-related diseases or arthritis (HR (95% CI); 0.87 (0.78–0.97), 0.89 (0.80–0.99), and
0.88 (0.78–1.00), respectively). The data did not support an association between ibuprofen use and prostate cancer risk.
CONCLUSION: Daily aspirin use, but not ibuprofen use, was associated with lower risk of prostate cancer risk.
British Journal of Cancer (2012) 107, 207–214. doi:10.1038/bjc.2012.227 www.bjcancer.com
Published online 21 June 2012
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Prostate cancer is the most common non-skin malignancy,
accounting for an estimated 29% of all newly diagnosed cancers
in 2012 among US men (Siegel et al, 2012). Despite the large
morbidity, the aetiology of prostate cancer remains unclear, with
only older age, African ancestry, family history of the disease, and
several loci in the 8q24 region as established risk factors (Hsing
and Chokkalingam, 2006; Witte, 2007; Cheng et al, 2008; Chu et al,
2008). Several lines of evidence also point to chronic inflammation
of the prostate as a potential predisposing factor, including data
suggesting that non-steroidal anti-inflammatory drug (NSAID) use
can inhibit prostate carcinogenesis (Stock et al, 2008; De Nunzio
et al, 2011). Non-steroidal anti-inflammatory drugs block the
conversion of arachidonic acid to prostaglandins, which are key
mediators of the inflammatory response, by inhibiting the enzyme
cyclooxygenase (COX, also called prostaglandin synthase; Smith
et al, 2000). Both COX-1 and COX-2 isoforms are expressed in
the human prostate (O’Neill and Ford-Hutchinson, 1993), with
*Correspondence: Dr FM Shebl; E-mail: fatma.shebl@yale.edu
Received 15 December 2011; revised 25 April 2012; accepted 25 April
2012; published online 21 June 2012

multiple reports of elevated COX-2 expression in prostate
adenocarcinoma relative to benign hyperplasia or normal tissue
(Gupta et al, 2000; Hsu et al, 2000; Madaan et al, 2000; Lee et al,
2001; Uotila et al, 2001). Some studies have further correlated
COX-2 expression with severe tumour grade (Madaan et al, 2000;
Lee et al, 2001), whereas others have found COX-2 overexpression
restricted to regions of prostatic proliferative inflammatory
atrophy (Zha et al, 2001). In addition, treatment of prostate
cancer cell lines with selective COX-2 inhibitors has been shown to
induce apoptosis (Liu et al, 1998, 2000; Hsu et al, 2000; Kamijo
et al, 2001), reduce angiogenesis (Liu et al, 2000), and inhibit
cellular invasion (Attiga et al, 2000).
Although some epidemiological studies have shown inverse
relationships between NSAID use and prostate cancer risk (Friis
et al, 2003; Sorensen et al, 2003; Garcia Rodriguez and GonzalezPerez, 2004; Mahmud et al, 2004, 2006, 2011; Jacobs et al, 2005,
2007, 2011; Bosetti et al, 2006; Dasgupta et al, 2006; Liu et al, 2006;
Cheng et al, 2007; Salinas et al, 2010; Dhillon et al, 2011), the risk
reductions have been modest and only some, not all, have yielded
statistically significant results (Nelson and Harris, 2000; Habel
et al, 2002; Roberts et al, 2002; Perron et al, 2003; Garcia Rodriguez
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and Gonzalez-Perez, 2004; Jacobs et al, 2005, 2007, 2011; Dasgupta
et al, 2006; Liu et al, 2006; Mahmud et al, 2006, 2011; Cheng et al,
2007; Dhillon et al, 2011). In addition, one study reported a
significant elevated risk of prostate cancer in association with
NSAID non-aspirin use (Murad et al, 2011). However, in a recent
meta-analysis (Mahmud et al, 2010), the summary odds ratios for
prostate cancer associated with aspirin use were 0.83 (95%
confidence interval (CI): 0.77–0.89) for all studies and 0.81 (95%
CI: 0.72–0.92) for advanced prostate cancer. The ORs associated
with non-aspirin NSAID for all studies or advanced prostate
cancer were 0.89 (95% CI: 0.78–1.08) and 0.98 (95% CI: 0.59–1.65),
respectively. The lack of clear consistency across studies of NSAID
use and prostate cancer risk may be explained by factors related to
study design, including choice of study population, exposure
definition and assessment, length of follow-up, prostate cancer
detection, and confounding. The observed differences in cancer
risk associated with aspirin relative to other NSAIDs may also be
attributed in part to pharmacological differences between individual NSAIDs.
Therefore, to overcome the shortcoming of previous studies, we
examined the relationship of aspirin and ibuprofen use with
subsequent risk of prostate cancer in a cohort of 29 450 men
participating in the screening arm of Prostate, Lung, Colorectal,
and Ovarian (PLCO) Cancer Screening Trial. The use of this cohort
provided us with prospective data on a wide range of topics,
including medical history, allowing for adjustment for several
putative confounders. In addition, men in the intervention arm
of the trial were uniformly screened for prostate cancer, therefore
minimising misclassification of the outcome. Previous studies may
have included occult cancers, which could cause participants to
increase their NSAID use, thereby masking the protective effect of
NSAID use due to reverse causality. The PLCO Cancer Screening
Trial, on the other hand, included few prevalent cancers owing to
its nature as a screening trial. Also, given the large number and
diversity of participants from 10 screening centres across the
United States, the PLCO Trial presented an opportunity to further
assess the relationship between NSAID use and prostate cancer
risk within a more broadly representative sample of the US
population than most previous studies. In addition, PLCO’s use of
active and passive surveillance and cause of death review process
allowed the most comprehensive ascertainment of study endpoints
including prostate cancer and death (Prorok et al, 2000).

Screening for prostate cancer occurred annually for 5 years after
the initial visit. Digital rectal examination was performed in the
first 3 years, while serum PSA levels were tested for 5 consecutive
years. Men with suspicious findings for prostate cancer (i.e., PSA
44 ng ml  1 or DRE with nodularity, indurations, or asymmetry of
the prostate gland) were referred for further diagnostic evaluation.
Medical record review was conducted by trained abstractors to
capture data on relevant diagnostic and therapeutic procedures
that occurred up to 1 year after cancer detection. Also as part of the
follow-up process, participants were mailed annual surveys that were
used to ascertain cancer incidence and death, and loss to follow-up
was established based upon failure to receive these completed surveys.
For completeness of follow-up, where available, prostate cancer
data were retrieved from the population-based cancer registries
serving the relevant study centre. Additional ascertainment of vital
status was conducted using the National Death Index. Underlying
cause of death was determined for all participants by unbiased
death review panels that were blinded to the study arm and not
affiliated with the study centre. The death review process entails
reviewing the death certificates, medical reports, and autopsy
reports. Pathological grade was assessed using the biopsy/resection
Gleason score (range 2–10). Clinical staging of patients were
determined using the TNM staging system (Fleming et al, 1997).
An aggressive cancer was defined as a Gleason score of 7 or higher,
or a stage III or IV case.
Of the 38 340 men randomised to the screening arm, we focused
our study on the 37 448 who had NSAID use data and who were
first screened for prostate cancer between November 1993 and July
2001. Men were excluded from the analysis if they (1) reported a
prior history of cancer at baseline, except non-melanoma skin
cancer (n ¼ 1726); (2) failed to complete the baseline risk factor
(n ¼ 892) and dietary (n ¼ 6586) questionnaires; (3) had no further
contact (i.e., no follow-up) after the baseline screening exam
(n ¼ 4107); and (4) had an insufficient dietary assessment (7452)
or 5) did not have adequate baseline PSA (n ¼ 4115). Men who
refrained from answering any question pertaining to NSAID use
(n ¼ 913) were additionally excluded (counts are not mutually
inclusive), resulting in a final study cohort of 29 450 men, with
3575 cases of prostate cancer identified in subsequent follow-up.
There were 546 cancers diagnosed within the first year of follow-up
and 3029 cancers diagnosed after the first year of follow-up.

Assessment of NSAID use

METHODS
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The PLCO Cohort detailed information on the PLCO Trial has been
published elsewhere (Gohagan et al, 2000; Prorok et al, 2000).
Approval of the trial protocol and procedures was granted by the
Institutional Review Boards of the National Cancer Institute and
the 10 screening centres (Birmingham, AL, USA; Denver, CO, USA;
Detroit, MI, USA; Honolulu, HI, USA; Marshfield, WI, USA;
Minneapolis, MN, USA; Pittsburgh, PA, USA; Salt Lake City,
UT, USA; St Louis, MO, USA; and Washington, DC, USA). All
participants provided written informed consent. Study eligibility
for men was restricted to those ages 55–74 who were not under
current treatment for any cancer (except basal and squamous cell
skin cancer); had no prior history of prostate, lung, or colorectal
cancer; had not undergone surgical removal of a lung or the
prostate or colon; had not taken Proscar (Finasteride) in the past 6
months; and were not already enrolled in another cancer screening
or prevention trial. This study was further limited to men
randomised to the screening arm.
At study entry, men were screened for prostate cancer by digital
rectal examination (DRE) and prostate-specific antigen (PSA)
testing. They also completed a brief, structured questionnaire on
risk factors for cancer and a 137-item food frequency questionnaire on diet and nutrient supplement use in the last 12 months.
British Journal of Cancer (2012) 107(1), 207 – 214

The baseline questionnaire included four questions that pertained
to aspirin and ibuprofen use: (1) During the last 12 months, have
you regularly used aspirin or aspirin-containing products, such
as Bayer, Bufferin, or Anacin? (Specific instruction was provided
to not count aspirin-free products, such as Tylenol or Panadol).
(2) During the last 12 months, how many pills of aspirin or aspirincontaining products did you usually take per day, per week, or per
month? (3) During the last 12 months, have you regularly used
ibuprofen-containing products, such as Advil, Nuprin, or Motrin?
and (4) During the last 12 months, how many pills of ibuprofencontaining products did you usually take per day, per week, or per
month? Possible responses for frequency of use of aspirin or
ibuprofen included none, o2 per month, 2–3 per month, 1 per
week, 2 per week, 3–4 per week, 1 per day, and 2 or more per day.

Statistical analysis
In our analysis, men were categorised separately for each NSAID
according to their reported frequency of use at baseline: never use,
1–29 pills per month (o1 pill per day), 1 pill per day, and X2 pills
per day. We also considered whether aspirin and ibuprofen were
used jointly or separately by creating another variable with
categories of neither, only regular aspirin use, only regular
ibuprofen use, and regular use of both NSAIDs.
& 2012 Cancer Research UK
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RESULTS
In this cohort, the mean age at entry was 62.8 (s.d. ¼ 5.3) years, with
a median (interquartile range) follow-up time of 11.7 (9.5,12.9) years.
& 2012 Cancer Research UK

Most men (490%) were Caucasian and college educated. The cohort
included 25 875 controls and 3575 prostate cancer cases. During the
study follow-up, 105 prostate cancer-related deaths and 4708 other
causes deaths were observed, with a median (interquartile range)
follow-up time of 5.0 (2.0–8.5) in cases and 12.2 (10.3, 12.9) in
controls. The age and race of men who did not respond to the NSAID
questions were not significantly different from responders. In the
following analyses, the use of aspirin or ibuprofen was assessed at the
study entry. For simplicity, in the remaining of the manuscript, we
will refer to these exposures as aspirin and ibuprofen use. On a daily
basis, aspirin was used more than ibuprofen, with only 1.2% of men
taking both drugs. For aspirin, 46% reported never use and 30.7%
reported use of X1 pill per day, whereas for ibuprofen, 75.2%
reported never use and 7.6% reported use of X1 pill per day.
As shown in Table 1, daily use of aspirin was greater with age:
26.6% for o60 years and 36.3% for X70 years. Although daily use
of ibuprofen was fairly consistent across age groups, the oldest
men used ibuprofen least often. Daily use of either aspirin or
ibuprofen was much less common among Asian/Pacific Islander
men than other racial groups. Frequency of NSAID use, however,
did not differ substantially by education or family history of
prostate cancer. There was also minimal variation in NSAID use by
smoking status, although use was most prevalent among current
cigarette smokers. Use of both aspirin and ibuprofen was greatest
among men with a baseline BMI of X30 kg m  2. The prevalence
of daily aspirin use was slightly higher with greater physical activity,
whereas the prevalence of daily ibuprofen use was lower. Daily
aspirin use was greatest among men with a history of cardiovascular-related conditions, including heart attack (72.5%), stroke
(60.2%), and hypertension (41.4%), and with a history of diabetes
(43.4%), whereas daily ibuprofen use was greatest among men with
a history of arthritis (14.9%).
The daily use of aspirin only was significantly associated with
lower risk of cancer HR (95% CI) of 0.91 (0.84–0.99). Although the
daily use of ibuprofen only showed similar trend, however, it was
not statistically significant 0.88 (0.65–1.20). Interestingly, the daily
use of aspirin plus ibuprofen was associated with excess risk of
prostate cancer 1.55 (1.13–2.13).
In multivariable analysis, the risks for prostate cancer associated
with taking oone pill and X1 pill of aspirin per day, relative to
never use, were 0.98 (95% CI, 0.90–1.07) and 0.92 (95% CI,
0.85–0.99), after adjusting for race, study centre, family history of
prostate cancer, number of screening exams, and ibuprofen use
(Table 2). We observed a significant negative trend with the
frequency of aspirin use (P for trend ¼ 0.04). As expected, in the
competing risk model, use of X1 pill of aspirin was associated
with excess risk of death, but with lower risk of prostate cancer
(HR (95% CI); 1.30 (1.21–1.39) and 0.92 (0.85–0.99), respectively).
Risks associated with daily aspirin use were similar but slightly
lower for aggressive than non-aggressive cancers. Although the
magnitude and strength of the association were slightly attenuated
when we excluded cancers diagnosed within the first year of
follow-up (HR (95% CI); oone pill 0.99 (0.90–1.09), and X1 pill
0.92 (0.84–1.0)), the HRs calculated for cancer diagnosed in the
first year of follow-up and in the remaining years of follow-up did
not differ significantly (P for interaction ¼ 0.56). There was no
evidence of an association between ibuprofen use and prostate
cancer risk.
History of various medical conditions including; diabetes,
hypertension, stroke, heart attack, arthritis, and colon polyp did
not appreciably modify the association between the use of either
NSAID and prostate cancer risk (data not in tables). However, in
stratified analysis, the inverse associations appeared more
pronounced among men taking at least one aspirin daily who
were older than 65 years with a HR (95% CI) of 0.87 (0.78–0.97)
and who reported having a history of cardiovascular-related
diseases HR (95% CI) ¼ 0.89 (0.80–0.99) or arthritis HR (95%
CI) ¼ 0.88 (0.78–1.00) despite the lack of significant interaction.
British Journal of Cancer (2012) 107(1), 207 – 214
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Hazard ratios (HRs) and 95% CIs for prostate cancer related to
the frequency of aspirin and ibuprofen use were estimated by Cox
regression with the HR modelled as a function of age (Korn et al,
1997). The follow-up period for each individual began from the
individual age at the baseline screening until the individual age at
the prostate cancer diagnosis, death, loss to follow-up, or the
administrative censor date (31 December 2009), whichever
occurred first. To examine dose response effects associated with
increasing frequency of use, trend tests were performed on a
continuous scale, where each category was assigned the value of
0, 1, y, and so on, and included in the model as a continuous
variable. Multivariate analyses were conducted to evaluate
potential confounding by age (modelled as the underlying
metric/time, that is, not as a covariate in the model); race (White,
Black, Asian/Pacific Islander, other); study centre; family history of
prostate cancer (yes, no); the number of screening exams in the
follow-up period; education (less than high school, high school
graduate, some college, college graduate, or higher); smoking
status (never, former cigarette use, current cigarette use, pipe, or
cigar use); baseline body mass index (BMI, o25.0, 25.0–29.9,
X30 kg m  2); physical activity (none, o1, 1, 2 þ hours per week);
total energy (kcal per day, in quintiles); various dietary factors
(grams per day, in quintiles, adjusted for energy using the residual
method (Willett and Stampfer, 1986)), including total b-carotene,
vitamin C, vitamin A, vitamin D, vitamin E, calcium, fat, red meat,
and lycopene; and self-reported history of various medical
conditions (yes or no), including hypertension, heart attack,
stroke, diabetes, arthritis, and colon polyps. Final multivariate
models were adjusted for age, race, study centre, family history of
prostate cancer, the number of screening exams, aspirin use (for
ibuprofen), and ibuprofen use (for aspirin). A variable remained in
the final model if it resulted in 410% change in the HR estimate
of NSAID. Calculated P-values were two-sided, with Po0.05
considered statistically significant.
To address the probability of reverse causality (i.e., individuals
with occult cancer might experience pain that lead to the use of
NSAID), which may lead to variation in the risk associated with
NSAID use in cancers diagnosed within the first year of follow-up
and cancers diagnosed after the first year of follow-up, analyses
were performed to estimate the risk of cancers diagnosed within
the first year of follow-up and cancers diagnosed after the first year
of follow-up in association with aspirin and ibuprofen use. The
significance of the difference in risk by time of cancer diagnosis
was tested by including an interaction term as cross product
between aspirin/ibuprofen and time of cancer diagnosis (as a
dummy variable of first year vs later years). Hazard ratios for nonaggressive and aggressive prostate cancers were also estimated,
such that for aggressive cancer, analysis was restricted to cases
with aggressive cancer compared with the controls. Similarly for
non-aggressive cancers analysis was restricted to cases with nonaggressive cancers and the controls. Prostatic tumours classified as
stage III or IV or designated Gleason scores of 7 or higher were
defined as aggressive (n ¼ 1560), whereas all other tumours were
defined as non-aggressive (n ¼ 2015). To address the possibility
that death may act as a competing risk, we conducted sensitivity
analysis where death was considered as a competing risk instead of
being a censoring variable (Andersen, 1993). Stratified analyses were
conducted to determine whether HRs associated with NSAID use
varied by age (o65, X65 years) and by history of selected medical
conditions (yes and no). Risk differences by race could not be
examined as 92.4% of the study population was White. Individuals
with missing data on any variable were excluded in the analysis.
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Table 1

Population characteristics by frequency of aspirin and ibuprofen use at baselinea
Aspirin use in last 12 months

Ibuprofen use in last 12 months

Never

o1 per
day

1 per
day

X2 per
day

n ¼ 13 539

n ¼ 6849

n ¼ 7604

n ¼ 1440

%

%

%

%

%

46.0

23.3

25.8

4.9

6 (5, 6)

6 (5, 6)

6 (5, 6)

6 (4, 6)

11.9
(9.7, 12.9)

12.0
(9.8, 12.9)

11.4
(9.3, 12.9)

Age at entry
55–59
60–64
65–69
70 þ

48.2
47.3
43.4
42.4

25.2
23.6
21.5
21.3

21.8
24.5
30.1
31.1

4.8
4.7
5.0
5.2

Race
White
Black
Asian/Pacific
Other

45.3
50.8
58.0
52.2

23.3
23.7
23.1
17.9

26.4
20.8
16.6
23.9

5.0
4.7
2.2
601

Education
Less than high school
High school graduate
Some college
College graduate or higher

46.2
46.1
45.8
46.1

20.9
21.9
23.9
23.8

26.1
26.6
25.4
25.8

6.9
5.4
4.9
4.3

Family history of prostate cancer
No
Yes

46.1
46.0

23.2
23.6

25.8
25.3

4.9
5.0

Smoking history
Never
Former cigarette use
Current cigarette use
Pipe or cigar use only

51.1
46.8
43.1
45.2

22.5
25.1
23.2
24.5

22.
21.9
28.6
26.0

4.0
6.2
5.2
4.4

Body mass index
o18.5–24.9
25.0–29.9
30.0 þ

49.5
45.3
43.9

24.0
23.6
21.4

22.5
26.4
28.4

4.1
4.6
6.3

Physical activity (per week)
None
o1 h
1h
2 or more hours

48.7
47.2
46.3
44.8

21.8
23.7
24.6
23.3

23.2
23.7
24.8
27.5

6.3
5.4
4.4
4.4

Medical history
Hypertension
Heart attack
Stroke
Diabetes
Arthritis
Colon polyps

37.5
17.2
28.5
38.7
42.8
43.6

21.1
10.4
11.2
17.9
22.1
23.1

35.8
67.2
52.7
37.5
27.1
28.8

5.6
5.3
7.5
5.9
8.0
4.5

Total
Number of screening exams
median (interquartile range)
Follow-up time median
(interquartile range)

o1 per
day

1 per
day

X2 per
day

n ¼ 5064

n ¼ 592

n ¼ 1634

%

%

%

75.2

17.2

2.0

5.6

6 (5, 6)

6 (5, 6)

6 (4, 6)

6 (5, 6)

11.5
(9.6, 12.9)

11.4
(9.2, 12.9)

11.5
(9.5, 12.9)

70.9
75.5
78.1
79.5

21.7
16.7
14.6
12.8

2.0
2.1
1.7
2.3

5.4
5.8
5.6
5.4

74.8
751
84.8
76.1

17.4
17.9
12.3
2246

2.0
2.9
0.8
0.0

5.8
4.1
2.2
1.5

75.3
74.9
74.4
76.0

14.2
16.9
17.8
17.5

2.4
2.2
2.1
1.8

8.2
6.1
5.7
4.7

75.5
74.2

17.0
17.7

2.0
2.0

5.5
6.2

78.9
74.3
73.5
74.0

14.7
18.2
18.3
17.8

1.6
1.9
2.3
2.0

4.6
5.6
6.0
6.2

79.8
74.9
70.9

14.8
17.7
18.9

1.5
2.0
2.6

3.9
5.5
7.6

74.5
73.5
74.8
76.0

16.8
18.0
17.9
17.0

2.1
2.1
2.0
2.0

6.6
6.4
5.3
5.0

74.4
78.4
80.4
73.9
65.9
74.5

16.9
14.3
11.8
17.4
19.3
17.5

2.6
2.1
1.9
2.2
3.6
1.7

6.1
5.2
5.9
6.5
11.3
6.3

Never
P-value n ¼ 22 113

0.01

11.5
o0.0001
11.8
(9.3, 12.9)
(9.5, 12.9)
o0.0001

n

29 540
o0.01
0.25

6 (5, 6)

11.7
(9.5, 12.9)

9129
9396
6959
3966
o0.0001

o0.0001

27 200
999
1184
67
o0.0001

0.80

2232
5423
9482
12 286
0.24

o0.0001

26 489
2241
o0.0001

o0.0001

8670
3127
15 324
2324
o0.0001

o0.0001

o0.0001
o0.0001
o0.0001
o0.0001
o0.0001
o0.01

P-value

o0.0001

o0.0001
Islander

Total

7544
14 736
6874
o0.001
4402
5125
3387
16 446
o0.0001
o0.0001
o0.01
0.14
o0.0001
0.26

9761
3768
695
2452
8687
2486

a

Row percentages.
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DISCUSSION
Data from this prospective cohort study suggest that regular use of
aspirin, but not ibuprofen, was associated with a reduced prostate
cancer risk. Overall decreases in prostate cancer risk associated
with regular aspirin use were modest, although there was some
British Journal of Cancer (2012) 107(1), 207 – 214

evidence of further risk reduction with more frequent use,
particularly among men who were older than age 65 or who had
a prior history of cardiovascular-related diseases or arthritis.
The lack of an association between ibuprofen use and prostate
cancer risk in this analysis is likely attributed in part to the low
prevalence of ibuprofen use in the PLCO cohort. Previous studies
& 2012 Cancer Research UK
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Table 2

HRs for prostate cancer in relation to frequency of aspirin and ibuprofen use in the 12 months before study entry
Aspirin

Total prostate cancer

Aggressive cancer

Non-aggressive cancer

Frequency of use
in last 12 months

Cases

RR

None
o1 per
X1 per
None
o1 per
X1 per
None
o1 per
X1 per

1669
848
1056
753
347
459
916
501
597

1.00
0.98
0.92
1.00
0.89
0.88
1.00
1.06
0.94

day
day
day
day
day
day

a

Ibuprofen

95% CI
Reference
0.90–1.07
0.85–0.99
Reference
0.78–1.02
0.78–0.99
Reference
0.95–1.19
0.85–1.04

P for trend

0.04*

0.05*

0.42

a

Cases

RR

2686
602
283
1182
248
128
1504
354
155

1.00
1.01
1.01
1.00
0.98
1.04
1.00
1.03
0.98

95% CI
Reference
0.93–1.11
0.89–1.14
Reference
0.85–1.13
0.86–1.25
Reference
0.92–1.17
0.83–1.15

P for trend

0.79

0.96

0.87

a

of ibuprofen have conflicting results. Although few studies
reported reduced risk of prostate cancer in association with nonaspirin NSAID use (Dasgupta et al, 2006; Mahmud et al, 2011),
some studies reported increased (Murad et al, 2011) or no risk
(Platz et al, 2005; Brasky et al, 2010). Laboratory data indicate that
both aspirin and ibuprofen can inhibit prostatic carcinogenesis
(Attiga et al, 2000; Andrews et al, 2002; Lloyd et al, 2003). In a
study that compared the effect of various non-prescription NSAIDs
(including aspirin and ibuprofen) on prostate tumour cell survival,
ibuprofen was the most effective in suppressing proliferation and
inducing apoptosis, particularly at clinically prescribed doses
(Andrews et al, 2002).
Owing to the potential adverse effects of aspirin, such as
gastrointestinal tract and renal toxicity, it is useful to identify
subgroups of men for whom use of aspirin is particularly
beneficial. In analyses restricted to men with a history of
cardiovascular-related diseases and men with a history of arthritis,
we observed inverse associations between frequency of aspirin use
and prostate cancer risk. Although the questionnaire lacked data
on specific dose and duration of NSAID use, our results of lower
risk among men older than 65 years and among those who have
history of cardiovascular diseases and arthritis suggest that the
reduction in prostate cancer risk is likely conferred by aspirin
taken at generally low doses (such as for cardiovascular disease)
for long duration (among older men). This notion is further
supported by the current common medical practice, where for the
purpose of coronary artery disease prevention doctors prescribe
the lower dose aspirin (81 mg day  1) for the majority of patients
(about 60%) and regular dose aspirin (325 mg day  1) for about
35% (Campbell et al, 2007)).
Several sources of bias, including confounding and detection
bias, could have affected the observed associations of aspirin and
ibuprofen use with prostate cancer risk. Men who take NSAIDs
daily for preventive purposes may be more health conscious and
more likely to engage in positive health-related behaviours, such as
maintaining a healthy diet and exercising regularly, which could
influence their risk for prostate cancer. However, controlling for
physical activity, dietary fat consumption, and other dietary
factors suspected to decrease prostate cancer risk, including
lycopene and vitamin E intake, did not materially alter the risk
estimates for either NSAID. Confounding may further exist if
NSAID use is related to a physical condition that directly affects
prostate cancer risk (Psaty et al, 1999). Although adjustment for
several factors, including arthritis and hypertension, did not alter
the results, residual confounding by unknown factors cannot be
ruled out.
The intriguing association between aspirin use and prostate
cancer risk among men with cardiovascular-related diseases merits
further investigation. Reasons for the inverse relation between
& 2012 Cancer Research UK

aspirin use and prostate cancer risk observed among men with
cardiovascular-related diseases are unknown, but recent studies
suggest that prostate cancer and cardiovascular disease share
common risk factors, such as hyperlipidemia and chronic
inflammation, and that regular statin use lowers the risk of
prostate cancer (Platz et al, 2006; Flick et al, 2007; Jacobs et al,
2007; Taylor et al, 2008). It should be noted that the prevalence of
daily aspirin use was greater among men who reported a history of
cardiovascular-related diseases or diabetes than men without these
conditions. In the PLCO cohort, diabetes, a major risk factor for
cardiovascular disease, had divergent relations with prostate
cancer by tumour aggressiveness. In these men, diabetes was
associated with a reduced risk of total prostate cancer but an
increased risk of aggressive prostate cancer among men who were
lean or physically active (Leitzmann et al, 2008). Additional
adjustment for history of diabetes, however, did not materially
change the association between aspirin use and prostate cancer
risk in our analysis.
Surveillance bias is possible but not likely to account for the
suggestive association between aspirin use and prostate cancer
risk. In theory, NSAID users, being either more health conscious or
more burdened with other medical problems, may be under closer
medical surveillance than non-users, thereby increasing their
chances for early detection of prostate cancer. Such bias, if any, is
likely minimal in our study, as men participating in the screening
arm of the PLCO Trial had an equal opportunity for cancer
detection – a unique difference from prior studies – with screening
visits scheduled annually over the first 5 years of follow-up. To
account for any residual difference in adherence to annual
screening between NSAID users and non-users, the total number
of screening visits across the follow-up period for each individual
was treated as a confounding variable (Weiss, 2003), but it yielded
no substantial change in the magnitude or direction of risk
associated with NSAID use.
Although recall bias was minimised by the prospective study
design, exposure misclassification could have occurred if there
were any changes in NSAID use related to symptoms of
undiagnosed prostatic disease within the last 12 months before
enrolment. This would be most likely to affect those men
diagnosed with prostate cancer earlier in the follow-up period.
Although excluding the 15% of cases who were diagnosed within
the first year of follow-up (i.e., probably prevalent cases) from the
analysis did weaken the association between daily aspirin use and
prostate cancer risk, there was no meaningful difference in the HRs
for cancers diagnosed within the first year of follow-up and
cancers diagnosed after the first year of follow-up. Another
unresolved issue is whether NSAIDs are more effective at
inhibiting tumour progression than initiation. Two studies have
suggested that frequent aspirin use reduces risk for advanced or
British Journal of Cancer (2012) 107(1), 207 – 214
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Abbreviation: CI ¼ confidence interval. Adjusted for race, study centre, family history of prostate cancer, the number of screening exams, aspirin use (for ibuprofen only),
and ibuprofen use (for aspirin only). *Significant at 0.05 level.
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metastatic prostate cancer (Norrish et al, 1998; Leitzmann et al,
2002). In contrast, another cohort study showed about a 24%
reduction in prostate cancer risk with daily aspirin use, the
magnitude of which did not differ between local and regional/
distant disease (Habel et al, 2002). Given that our male cohort
originated from the screening arm of the PLCO Trial, participants
were screened annually. Therefore, cancer cases were more likely
to be caught early. Thus, few cases of metastatic cancer were
diagnosed, with almost half of the metastatic cancer cases detected
within 1 year of the initial screening visit. Under these
circumstances, only regular aspirin use in relation to advanced
prostate cancer could be examined. We found a slightly lower risk
for aggressive compared with non-aggressive tumours, indicating
that aspirin might be more influential in hindering the progression
than development of prostatic tumours.
Even though the underlying mechanisms have yet to be precisely
delineated, the potential benefit of aspirin does support the
prevailing hypothesis that chronic inflammation contributes to
prostate carcinogenesis. As a response in the repair of damaged or
infected prostatic tissue, chronic inflammation may promote
neoplastic development and growth by triggering specific cytokines and growth factors, activating COX-2 in macrophages and
epithelial cells, and inducing oxidative stress (Lucia and Torkko,
2004). Accordingly, increasing attention has been devoted to the
focal lesions of epithelial atrophy associated with chronic
inflammation and a high proliferative index, collectively known
as proliferative inflammatory atrophy. These lesions have been
commonly observed in the peripheral zone of the prostate where
most tumours originate, found in close proximity to both
adenocarcinoma and high-grade prostatic intraepithelial neoplasia, and associated with COX-2 upregulation (Zha et al, 2001; Platz
and De Marzo, 2004).
Despite numerous strengths, including low attrition, nearly
complete histological confirmation of cancer cases, comprehensive
baseline data on potential confounders, and equal access for
prostate cancer screening among participants, this study had
several limitations. Data on frequency of aspirin and ibuprofen use
were collected at a single point in time (during the last 12 months),
without record of dose (pill count), duration, or indication for use.
Therefore, there might be some misclassification of NSAID use
because the assessment relied only on baseline self-reports.
However, although there might be an underestimation because
people tend to increase the frequency or the dose of use of NSAID
by age, this underestimation is expected to be non-differential
because the reporting was before the development of cancer. In
fact this underestimation, if it biased our results at all, would bias
the results towards the null. Thus, our estimates are conservative.
In addition, misclassification might have occurred because of the
use of some prescription and/or over-the-counter NSAID that the
respondent might overlooked. However, if there is misclassification, it would most likely be non-differential, therefore potentially
attenuating our results.
The prevalence of regular aspirin use in this study (31%),
nevertheless, was comparable to that noted in the other US-based
cohort studies of prostate cancer, which ranged from 17% (for
daily use) to 59% (for use in the past month; Paganini-Hill et al,
1989; Schreinemachers and Everson, 1994). In a US study on

patterns of aspirin use among adults ages 45–64, the prevalence of
aspirin use among white men was 31%, with increasing trends in
prevalence noted both across the study period (1987 to 1989) and
with older age. In addition, a recent report from the Household
Component of the Medical Expenditure Panel Survey by the
Agency for Health Care Research and Quality concluded that
19.3% of the adult US non-institutionalised individuals report
aspirin use either daily or every other day. The use increases by
age, and almost 50% of individuals older than 65 years old
reported daily use (Soni, 2007). Exposure assessment was also
limited by not taking into account the use of other specific NSAIDs
and by not verifying self-reported data on NSAID use through
medical record review. However, misclassification due to the use of
COX-2 selective inhibitors, such as celecoxib and rofecoxib, was
probably minimal, as these ‘new generation’ NSAIDs were first
introduced in 1999, which was toward the end of the trial
recruitment period. Although the extent and impact of exposure
misclassification cannot be determined, extensive measurement
error would most likely lead to risk attenuation.
In addition, as the majority of the participants are White, the
results might not be generalisable to other races. Another limitation of
this type of data is left truncation, such that participants who enter the
cohort at a certain age have obviously not died or developed cancer
before that age. Subjects who died or developed cancer before
enrolment would clearly not be included in the cohort, thus resulting
in left truncation. However, we used PROC PHREG in SAS/STAT
software (Version 9.2, SAS Institute Inc., Cary, NC, USA), which
allows late entry models. This analysis method handles the left
truncated data therefore alleviates this limitation.
Another limitation that should be noted is the competing
mortality due to aging or other medical conditions. However, in
the competing risk sensitivity analysis, the inverse associations we
observed between NSAID use and prostate cancer are unlikely to
be due to an increased risk of death among men who take NSAIDs;
since the results were essentially the same for the analysis with and
without death included as a competing risk.
In summary, this prospective cohort study suggests that aspirin
use was associated with a reduced prostate cancer risk, in particular,
in certain subgroups of men. Additional studies with more detailed
exposure measurement are warranted to evaluate the dose, duration,
and timing of NSAID use in relation to prostate cancer risk.
The association between non-selective and selective COX-2 inhibitors, as well as non-COX inhibitors, should also be investigated.
Coupled with laboratory-based research, these efforts should further
expand our knowledge of the mechanisms by which NSAIDs,
particularly aspirin, may influence prostate carcinogenesis.
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